MedTrace Logo

Pembrolizumab, Carboplatin and Cabazitaxel in Aggressive Metastatic Castration Resistant Prostate Cancer (PEAPOD_FOS)

NCT05563558 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2024-06-11

No results posted yet for this study

Summary

It is a Phase 2 clinical trial of Pembrolizumab in combination with Carboplatin and Cabazitaxel in Aggressive Variant Metastatic Castration Resistant Prostate Cancer.

It is divided into two parts: an induction period of 6 cycles of 3 weeks each cycle of Pembrolizumab+Cabazitaxel+Carboplatino and a maintenance phase of 15 cycles of 6 weeks each cycle of Pembrolizumab.

Conditions

  • Prostate Cancer Metastatic

Interventions

DRUG

Pembrolizumab

Included in arm/group description

DRUG

Carboplatin

Included in arm/group description

DRUG

Cabazitaxel

Included in arm/group description

Sponsors & Collaborators

  • Fundacion Oncosur

    lead NETWORK

Principal Investigators

  • Enrique Gonzalez-Billalabeitia, Dr · Hospital Universitario 12 de Octubre, Madrid

  • Teresa Alonso Gordoa, Dr · Hospital Universitario Ramón y Cajal

  • Álvaro Pinto Marín, Dr · Hospital Universitario La Paz

  • Ignacio Durán Martínez, Dr · Hospital Universitario Marqués de Valdecilla

  • Begoña Mellado González, Dr · Hospital Clinic of Barcelona

  • David Lorente Estellés, Dr · Hospital Provincial De Castellón

  • Albert Font Pous, Dr · ICO- Badalona

  • Sergio Vazquez Estévez, Dr · Hospital Lucus Augusti

  • Javier Puente, Dr · Hospital San Carlos, Madrid

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-05-05
Primary Completion
2026-11-01
Completion
2026-11-01

Countries

  • Spain

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05563558 on ClinicalTrials.gov